ClinicalTrials.gg
RecruitingNCT07076082VSTAR-PUpdated Jul 16, 2026

Vascular Trial Associated Registry Pilot

A Phase 4 interventional study of Clopidogrel (Plavix) Pharmacogenetic Test Reagents in Peripheral Arterial Disease, sponsored by Corewell Health West. Recruiting at 2 sites in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Corewell Health West · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing clopidogrel in Peripheral Arterial Disease — 3 open to participants now, 4 under way, none of them phase 3. Clopidogrel · Peripheral Arterial Disease.

Planned enrollment
4th of 10
350 · median 205
Started
2025
with 2 others
Phase 4
4 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Corewell Health West

Among the 10 studies testing clopidogrel in Peripheral Arterial Disease, this one is the 4th largest by planned enrollment, is one of 3 that started in 2025, is one of 4 in phase 4, and was the 8th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

3 of the 10 studies testing clopidogrel in Peripheral Arterial Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About clopidogrel

Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing clopidogrel in Peripheral Arterial Disease, or all of them as a file.
02

Study summary

The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.

Read the detailed description

The Main Objective of this study is to create an investigator-initiated, multicenter, open label, randomized trial to evaluate 1 month vs. 6 months of DAPT in patients undergoing lower extremity endovascular revascularization. The randomization will be 1:1 within one strata (diabetes yes/no), using blocks of varying sizes. All patients will be on DAPT for one month. At the time of the one-month visit, eligible patients who consent will be randomized to single antiplatelet therapy (SAPT) indefinitely (Arm 1) or to DAPT for 5 more months (followed by SAPT) (Arm 2). Follow-up will continue for 12-months post-procedure and will include assessment of MACE and MALE, as well as adverse bleeding events. Data for this trial will be collected via nested participation in the VQI Peripheral Vascular Intervention (PVI) registry's existing Procedural and Follow-up data collection modules.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • Peripheral Vascular Disease (PVD), Peripheral Vascular Intervention (PVI), Dual Antiplatelet therapy (DAPT), Peripheral Arterial Disease (PAD)
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 45 at time of enrollment
  • Patient is scheduled for a PVI or has recently had a PVI in the last 30 days
  • Patient data is being submitted to Fivos, who is acting as the data collection subcontractor for the VQI-PVI registry.
  • Atherosclerotic vascular disease

Exclusion criteria

Exclusion Criteria:

  • Patients who cannot consent for themselves
  • Allergy to Clopidogrel
  • Patients unable to stop clopidogrel for other medical reasons
  • Patients on dual pathway inhibition (DPI) with low dose rivaroxaban (2.5mg twice a day) that are unable to stop these medications
  • Allergy to aspirin
  • Nonatherosclerotic vascular disease
  • Patients undergoing open bypass at the same time as the peripheral transcutaneous angioplasty
  • Patients with high bleeding risk (HBR) defined as:

    • History of major bleeding, active bleeding disorder, severe renal impairment ( \<30), concurrent anticoagulation, count \<100,000
    • Recent stroke (within 6 months)
    • Current warfarin therapy or full dose therapeutic direct oral anticoagulants (DOAC).
  • Patients unwilling or unable to comply with standard of care follow-up visits
  • Pregnant women
  • Prisoners
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Active comparator
    Dual antiplatelet therapy 1-Month followed by single antiplatelet therapy indefinitely

    Aspirin and Clopidogrel (Plavix) for 1-month post-procedure followed by Aspirin indefinitely. Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (Plavix) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).

    Drug: Clopidogrel (Plavix) Pharmacogenetic Test Reagents

  • Active comparator
    Dual antiplatelet therapy 6-Month followed by single antiplatelet therapy indefinitely

    Aspirin and Clopidogrel (Plavix) for 6-months post-procedure followed by Aspirin indefinitely. Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (Plavix) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).

    Drug: Clopidogrel (Plavix) Pharmacogenetic Test Reagents

Interventions

  • DrugClopidogrelStudies of ClopidogrelClopidogrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (clopidogrel) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).

06

What researchers measure

Primary outcomes

  1. The proportion of patients eligible who are offered study enrollment

    Patients who undergo PVI that meet inclusion criteria and are offered enrollment.

    Time frame: 1 year

  2. The proportion of eligible patients who consent to enrollment and randomization

    Patients who meet inclusion criteria and agree to participate in trial vs those that do not agree to participate in trial

    Time frame: 1 year

  3. The proportion of enrolled patients who have the primary (composite) event of interest defined at 6 months

    The number of enrolled patients that have the occurrence of one of the following stroke, myocardial infarction, major amputation (above ankle), urgent revascularization (thrombolysis, endovascular therapy, or surgical bypass), or loss of patency of the target vessel.

    Time frame: 6-months

  4. The proportion of enrolled patients who have the primary (composite) event of interest defined at 12 months

    The number of enrolled patients that have the occurrence of one of the following stroke, myocardial infarction, major amputation (above ankle), urgent revascularization (thrombolysis, endovascular therapy, or surgical bypass), or loss of patency of the target vessel.

    Time frame: 1 year

  5. The numbers and proportions of patients who have each type of major event

    Of the enrolled patients that have a medical primary event how many individuals were in each category stroke, myocardial infarction, major amputation (above ankle), urgent revascularization (thrombolysis, endovascular therapy, or surgical bypass), or loss of patency of the target vessel.

    Time frame: 1 year

  6. The proportions of patients who have major event status recorded at each observation time

    Major event status at 1, 6-months post PVI and 12-month post PVI

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Aday AW, Gutierrez JA. Antiplatelet Therapy Following Peripheral Arterial Interventions: The Choice Is Yours. Circ Cardiovasc Interv. 2020 Aug;13(8):e009727. doi: 10.1161/CIRCINTERVENTIONS.120.009727. Epub 2020 Aug 14. No abstract available. PubMed 32791949 ↗
  • Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007 May 15;49(19):1982-8. doi: 10.1016/j.jacc.2007.03.025. Epub 2007 Apr 11. PubMed 17498584 ↗
  • Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics. 2004;22 Suppl 4:19-27. doi: 10.2165/00019053-200422004-00005. PubMed 15876009 ↗
  • Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, Chandra V, Drachman DE, Eaves JM, Ehrman JK, Evans JN, Getchius TSD, Gutierrez JA, Hawkins BM, Hess CN, Ho KJ, Jones WS, Kim ESH, Kinlay S, Kirksey L, Kohlman-Trigoboff D, Long CA, Pollak AW, Sabri SS, Sadwin LB, Secemsky EA, Serhal M, Shishehbor MH, Treat-Jacobson D, Wilkins LR; Peer Review Committee Members. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jun 11;149(24):e1313-e1410. doi: 10.1161/CIR.0000000000001251. Epub 2024 May 14. PubMed 38743805 ↗
  • Writing Committee Members; Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, Chandra V, Drachman DE, Eaves JM, Ehrman JK, Evans JN, Getchius TSD, Gutierrez JA, Hawkins BM, Hess CN, Ho KJ, Jones WS, Kim ESH, Kinlay S, Kirksey L, Kohlman-Trigoboff D, Long CA, Pollak AW, Sabri SS, Sadwin LB, Secemsky EA, Serhal M, Shishehbor MH, Treat-Jacobson D, Wilkins LR. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-2604. doi: 10.1016/j.jacc.2024.02.013. Epub 2024 May 14. PubMed 38752899 ↗
  • Tsai SY, Li YS, Lee CH, Cha SW, Wang YC, Su TW, Yu SY, Yeh CH. Mono or Dual Antiplatelet Therapy for Treating Patients with Peripheral Artery Disease after Lower Extremity Revascularization: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel). 2022 May 12;15(5):596. doi: 10.3390/ph15050596. PubMed 35631422 ↗
  • Nguyen T, Jokisch C, Dargan C, Janjua H, Brooks J, Moudgill N, Latz C, Shames M. The Effects of Clopidogrel Duration on Carotid Artery In-Stent Restenosis. Ann Vasc Surg. 2024 Jun;103:68-73. doi: 10.1016/j.avsg.2023.12.064. Epub 2024 Feb 11. PubMed 38350539 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 28 phase 4 interventional studies under Peripheral Arterial Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 21, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07076082
Lead sponsor
Corewell Health West
Collaborators
Henry Ford Hospital
Responsible party
Vikram Kashyap (Vice President, Cardiovascular Health, Frederik Meijer Heart and Vascular Institute, Corewell Health West) — Principal investigator
First posted
Jul 21, 2025
Start date
Oct 15, 2025
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Jul 16, 2026

Study contacts

Stephen C Orey, MS
Contact
Stephen.orey@corewellhealth.org
6163916660
Vikram C Kashyap, MD
principal investigator · Corewell Health West

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion